Proteome Sciences plc (LON:PRM) insider Martin Diggle purchased 500,000 shares of the firm’s stock in a transaction dated Friday, November 16th. The shares were bought at an average cost of GBX 3 ($0.04) per share, with a total value of £15,000 ($19,600.16).

Martin Diggle also recently made the following trade(s):

  • On Thursday, November 8th, Martin Diggle purchased 313,957 shares of Proteome Sciences stock. The shares were bought at an average cost of GBX 3 ($0.04) per share, with a total value of £9,418.71 ($12,307.21).

PRM stock opened at GBX 3.32 ($0.04) on Tuesday. Proteome Sciences plc has a twelve month low of GBX 2.61 ($0.03) and a twelve month high of GBX 5.64 ($0.07).

Separately, FinnCap reissued a “corporate” rating on shares of Proteome Sciences in a research report on Tuesday, November 6th.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at

Proteome Sciences Company Profile

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers. It delivers content for personalized medicine in the areas of biomarker services, biomarker assays, isobaric and isotopic reagents, and proprietary biomarkers. The company designs, performs, and interprets high resolution proteomics studies to improve target discovery, validation, and mechanism of action studies; offers specialized services to enhance discovery and validation of mechanistic biomarkers in peripheral fluids; and provides a set of bioinformatics tools to enhance data integration, and select regulated features and map to biological processes.

Featured Story: How to Calculate Compound Annual Growth Rate (CAGR)

Receive News & Ratings for Proteome Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteome Sciences and related companies with's FREE daily email newsletter.